FDA Clears Magstim Transcranial Magnetic Stimulation System  Horizon 3.0 with StimGuide Pro

 // News

January 30  

MINNEAPOLIS, Minn. & Carmarthenshire, UK — (January 30, 2024) – Magstim, the  global leader in neuroscience research and treatment for mental health, has been  awarded FDA clearance for the Horizon 3.0 with StimGuide Pro. This provides  physicians, nurse practitioners, clinicians, and researchers with the most advanced  transcranial magnetic stimulation technology (TMS) available to treat patients  diagnosed with depressive or obsessive-compulsive conditions*.

“With just one screen, this system is simple to use and navigate,” said Anthony Baldwin  Polizzi, Senior TMS Technician, My Psychiatrist, Florida, USA. “The new Bluetooth  anatomical pointer makes it easy to map and treat patients. I like it a lot.” 

The first integrated TMS system with navigation, Horizon 3.0 with StimGuide Pro builds  on the current successful H 3.0 platform used by practices worldwide, and adds new  advanced camera technology, software designed to allow for precise treatment  targeting. All patient treatments and technology are now centralized on one screen,  designed to reduce complexity, and provide a greater focus on patient care. 

TMS non-invasive brain stimulation uses an electromagnetic coil to stimulate nerve cells  in the region of the brain involved in mood control and depression. 

Magstim developed the first TMS system more than 30 years ago, used in more than 16,000 neuroscientific and clinical research studies. Thousands of physicians, nurse  practitioners, researchers and mental health professionals worldwide use Magstim TMS  to treat patients.

StimGuide Pro advanced navigation is designed to improve coil positioning for  repeatability and accuracy. New camera and navigation workflow ensure magnetic  pulses are delivered to targeted brain regions, improving patient outcomes. Magstim  Connect enables multiple compatible systems to be managed from one central system. 

“We are passionate about helping patients worldwide to improve their mental health,”  said Ronnie Stolec-Campo, CEO, Magstim. “We worked with leading psychiatrists,  clinicians, and researchers to develop this system, enabling advance treatments and  simplify practice workflows. TMS is life-saving technology that provides non pharmacological, non-invasive treatments.” 

To learn more, visit Magstim.com or call 844-624-7846. 

About Welcony 

Globally, Welcony technologies have supported thousands of research labs, clinics, hospitals and  universities that focus on mental health, brain disorders, cognitive neuroscience and neuromonitoring.  Key brands include Magstim Magnetic Stimulation, MagstimEGI high-density EEG, Technomed Clinical  Neurophysiology and Neurosign Nerve Safety Monitoring. Welcony is backed by Telegraph Hill Partners,  a San Francisco based private equity company. 

*Horizon 3.0 with S0mGuide Pro is indicated for the treatment of Major Depressive Disorder in adult  pa0ents who have failed to achieve sa0sfactory improvement from prior an0depressant medica0on in  the current episode, as well as an adjunct for the treatment of adult pa0ents suffering from Obsessive Compulsive Disorder. 

Note: The Horizon 3.0 TMS Therapy System has also received prior clearance in K223154 for decreasing anxiety  symptoms for those who may exhibit comorbid anxiety symptoms in adult paEents suffering from MDD. 

# # # #

Success message!
Warning message!
Error message!